When someone receives a micro dose of a GLP-1 agonist, they are essentially utilizing a small dose of the medication to help jump start the metabolism and other health changes
This will involve submitting a request to your insurance company explaining why the medication is medically necessary
These PSGs focus on peptide drugs used to treat conditions such as obesity, type 2 diabetes, osteoporosis, and macular degeneration
For an individual weighing 250 pounds, this equates to a potential weight loss ranging from 37 to 50 pounds
Key findings: ~50% of women with GDM developed Type 2 diabetes within 1 year after delivery 60% required insulin or metformin during pregnancy Very number of women had choosen C-section deliveries (to avoid complications related long normal vaginal delivery) Low birth weight babies were more common than expected, contrary to the common belief of only large babies in GDM Risk factors identified: Higher maternal age (mean 37 years) Higher BMI (mean 31) Family history of diabetes Additional observations: 33% had hypertension 69% had hypothyroidism 16% conceived via IVF 24% babies had low birth weight Key message: Gestational diabetes often signals a future risk of Type 2 diabetes
Mechanistically, dampening the inflammatory chemicals that interfere with insulin signaling should improve how your cells respond to insulin